Norepinephrine: the next therapeutics frontier for Parkinson's disease

Tissue concentrations of norepinephrine (NE) are markedly decreased in various regions of the Parkinson's disease (PD) brain. As in the substantia nigra pars compacta, neuronal dropout and Lewy bodies are prominent changes affecting the locus coeruleus, which is the source of ascending NErgic projections. Despite the major roles of NE throughout the brain, there has been only minimal exploration of pharmacological intervention with NErgic neurotransmission. Cognitive operations, "freezing" of gait, tremor, dyskinesia, REM sleep regulation, and other aspects of brain function are tied into signaling by NE, and there is also evidence that it may have a role in the neurodegenerative process itself. This article reviews the reported pharmacological experience in PD therapeutics.

[1]  Bernard Pillon,et al.  Cognitive deficits in Parkinson’s disease , 1996, Journal of Neurology.

[2]  M. Kilbourn,et al.  Reduced MPTP neurotoxicity in striatum of the mutant mouse tottering , 1998, Synapse.

[3]  Y. Agid,et al.  Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[4]  E. Tolosa,et al.  Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode. , 2006, General hospital psychiatry.

[5]  J. Greenfield,et al.  THE BRAIN-STEM LESIONS IN PARKINSONISM , 1953, Journal of neurology, neurosurgery, and psychiatry.

[6]  M. Millan,et al.  Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats byα1 as compared toα2 agonists and antagonists , 1991, Brain Research.

[7]  J. Greenfield,et al.  THE BRAIN-STEM LESIONS IN PARKINSONISM , 1953, Journal of neurology, neurosurgery, and psychiatry.

[8]  P. Riederer,et al.  Oxidative stress: free radical production in neural degeneration. , 1994, Pharmacology & therapeutics.

[9]  Nora Turjanski,et al.  Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. , 2005, Brain : a journal of neurology.

[10]  T. H. Burnstine,et al.  Movement Disorders 2 , 1988, Neurology.

[11]  Y. Agid,et al.  Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. , 1998, Clinical neuropharmacology.

[12]  Eduardo E. Benarroch,et al.  The locus ceruleus norepinephrine system , 2009, Neurology.

[13]  Udo Rüb,et al.  Where Does Parkinson Disease Pathology Begin in the Brain? , 2002, Journal of neuropathology and experimental neurology.

[14]  T. Chase,et al.  Peripheral beta‐adrenergic blockade treatment of parkinsonian tremor , 1984, Annals of neurology.

[15]  Melissa Gerstenhaber,et al.  Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study , 2009, Movement disorders : official journal of the Movement Disorder Society.

[16]  G. Corsini,et al.  Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. , 1995, European journal of pharmacology.

[17]  V. Chan‐Palay,et al.  Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression , 1989, The Journal of comparative neurology.

[18]  F. Fornai,et al.  The role of the locus coeruleus in the development of Parkinson's disease , 2000, Neuroscience & Biobehavioral Reviews.

[19]  N. Foster,et al.  CSF dopamine‐‐hydroxylase activity in Parkinson's disease , 1985, Neurology.

[20]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[21]  F. Colpaert,et al.  Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. , 1993, European journal of pharmacology.

[22]  C. Mathias.  L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension , 2008, Clinical Autonomic Research.

[23]  K. Rommelfanger,et al.  Norepinephrine: The redheaded stepchild of Parkinson's disease. , 2007, Biochemical pharmacology.

[24]  G. Aston-Jones,et al.  Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat , 2005, Journal of Neural Transmission / General Section JNT.

[25]  P. Jäkälä,et al.  The α2 agonist, clonidine, improves spatial working memory performance in Parkinson's disease , 1999, Neuroscience.

[26]  Y. Agid,et al.  Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease , 1996, Neurology.